Summit shows mixed results from key study of lung cancer drug Ivonescimab has been closely tracked for its blockbuster potential ++

https://www.statnews.com/2025/05/30/summit-shows-ivonescimab-lung-cancer-mixed-results/ Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials The companies are looking for their next Dupixent https://www.statnews.com/2025/05/30/itepekimab-sanofi-regeneron-copd-dupixent-aerify/